The third edition of the ILCA School of Liver Cancer jointly organised by the Bologna University, Bologna Liver Oncology Group (BLOG)  on 18-19 May 2018 at the S.Orsola-Malpighi Hospital in Bologna, Italy, was a great success with around 140 participants coming from 12 different countries.

The ILCA School 2018 focused on Hot Topics in Clinical Management of Primary Liver Cancer.

The S.Orsola-Malpighi Hospital in Bologna is one of the largest Italian hospital in Italy and the one with the longest tradition in the diagnostic and therapeutic management of hepatocellular carcinoma, which has brought to the current internationally recognised expertise and innovative scientific activities.

Learning objectives

Who attended?

Fellows in gastroenterology and hepatology training programmes, junior faculty, basic/translational researchers and experienced clinicians with a desire to become more involved in liver cancer investigation and care.

The ILCA School of Liver Cancer 2018 was an initiative organised thanks to an unrestricted educational grant from Bayer Healthcare.

Friday, 18 May
09:00 Opening remarks
L. Bolondi (Italy)
Session 1 – The Role of Circulating and Tissue Biomarkers
Chair: J. Zucman-Rossi (France)
09:10 – 09:30 Predicting the development of HCC in liver cirrhosis
E. Villa (Italy)
9:30 – 09:50 Circulating MiRNA for the diagnosis and staging of HCC
L. Gramantieri (Italy)
9:50 – 10:00 Discussion
Session 2 – NAFLD and HCC
Chair: S. Bellentani (Switzerland)
10:00 – 10:20 Risk of cirrhosis and HCC in NAFLD: can be predicted and/or quantified?
J.F. Dufour (Switzerland)
10:20 – 10:40 Genetic factors associated with HCC in NASH
L. Valenti (Italy)
10:40 – 11:15 Recommendations for screening or surveillance for NAFLD
E. Bugianesi (Italy)
11:15 – 11:30 Break
Session 3 – Diagnostic Dillemas
Chairs: R. Golfieri (Italy) and F. Trevisani (Italy)
11:30 – 11:50 Time for new parameters in MRI for the diagnosis of HCC?
R. Golfieri (Italy)
11:50 – 12:10 LI RADS classification system, the issue of cholangiocarcinoma
F. Piscaglia (Italy)
12:10 – 12:20 Discussion
12:20 – 13:00 Round table debate starting from clinical cases
Management of undefined small nodular liver lesion in cirrhosis
Chair: L. Bolondi (Italy)
Discussants: M. Cescon (Italy), J.F. Dufour (Switzerland), F. Piscaglia (Italy) and M. Renzulli (Italy)
13:00 – 14:00 Lunch Break
Session 4 – Antiviral Treatment and HCC
Chairs: P. Andreone (Italy), J. Bruix (Spain)
14:00 – 14:20 Treatment of HBV with antivirals and influence on the risk of HCC
P. Lampertico (Italy)
14:20 – 14:40 Risk of development and natural history of HCC arisen in HCV patient
with SVR after interferon based treatment

S. Bhoory (Italy)
14:40 – 15:00 Treatment of chronic hepatitis C with IFN-free DAA regimens and risk of HCC
M. Colombo (Italy)
15:00 – 15:45 Strategies for treatment of HCV with DAA after curative HCC treatment
I do always treat

C. Cammà (Italy)
I do not treat
M. Reig (Spain)
Sometimes I treat

P.R. Galle (Germany)
15:45 – 16:00 Discussion
16:00 – 16:20 Break
Session 5 – Challenges in Current Systemic Therapy for HCC
Chairs: P.J. Johnson (United Kingdom) and L. Rimassa (Italy)
16:20 – 16:40 Is it possible to compare the multiple treatments tested for HCC?
The Network Metanalysis model

A. Cucchetti (Italy)
16:40 – 17:00 Is efficacy of Sorafenib and Regorafenib predictable?
M. Reig (Spain)
17:00 – 17:20 Stopping rules for Sorafenib in the era of Regorafenib
P.J. Johnson (United Kingdom)
17:20 – 17:40 Treatment of HCC in Child-Pugh B class
F. Trevisani (Italy)
17:40 – 18:00 Discussion
18:00 – 18:30 Round table debate starting from clinical cases
Management of advanced HCC in patients with comorbidities
Case presentations
F. Tovoli (Italy)
Expert discussants
B. Daniele (Italy), M. Reig (Spain) and F. Trevisani (Italy)
18:30 Closure of the day
Saturday, 19 May
Session 6 – A Look into the Future of HCC
Chair: L. Bolondi (Italy) and J-F. Dufour (Italy)
08:30 – 08:50 The role of Radioembolization
M. Seidensticker (Germany)
08:50 – 09:10 New molecular targets for systemic therapy
J. Zucman-Rossi (France)
09:10 – 09:30 Background and clinical perspectives of immune check-point inhibitors
P.R. Galle (Germany)
09:30 – 09:50 Postprogression survival and design of second or third line trials in 2018
J. Bruix (Spain)
09:50 – 10:10 Recently concluded and ongoing trials for systemic therapy
checkpoint of HCC in 2018: current standpoint

L. Bolondi (Italy)
10:10 – 10:30 Discussion
10:30 – 10:50 Break
Session 7 – The Emerging Issue of Cholangiocarcinoma
Chair: P.J. Johnson (United Kingdom) and F. Piscaglia (Italy)
10:50 – 11:10 Development of HCC and ICC.
Molecular pathways with a perspective of clinical relevance

J.C. Nault (France)
11:10 – 11:50 Indications for surgery
M. Cescon (Italy)
11:50 – 12:10 Treatment of mass-forming non surgical intrahepatic cholangiocarcinoma
L. Rimassa (Italy)
12:10 – 12:30 Locoregional treatment of non surgical obstructive cholangiocarcinoma of the main bile ducts
R. Golfieri (Italy)
12:30 – 12:50 Discussion
12:50 Closure of the meeting


The venue of the ILCA School of Liver Cancer 2018 is the General and University Hospital, S.Orsola-Malpighi in Bologna, Italy.

Venue Address

General and University Hospital, S.Orsola-Malpighi
Aula Magna Nuove Patologie – Pad 5
S. Orsola Malpighi Hospital – Via Massarenti, 9
40125 Bologna

The venue is located 10 minutes from Bologna’s city centre. It can easily be reached by means of public transportation system.

Click here to find the directions.


Please find below a list of suggested hotels all within walking distance from the venue.

Please note that ILCA has not blocked any rooms at a preferred rate for these hotels. Therefore, we recommend booking early to ensure availability. Please contact the hotel directly to make your reservation.